A 17-year-old female presented with a very rare case of primary Ewing's sarcoma of the skull involving the occipitotemporal region. Systemic examination found no evidence of metastasis. The tumor was surgically removed, and the patient underwent radiotherapy and chemotherapy. Fourteen months after surgery there has been no recurrence of the tumor. Cranial primary Ewing's tumor has a good prognosis after radical surgery and adjuvant therapy.
Introduction
Ewing's sarcoma is an uncommon primary bone tumor usually encountered by orthopedic surgeons, but is rare in neurosurgical practice. Only 22 cases of primary cranial Ewing's sarcomas have been reported [1] [2] [3] 5, [8] [9] [10] [11] [12] 14, [16] [17] [18] [19] 21, 22, [31] [32] [33] in addition to a series of 14 patients with primary cranial Ewing's sarcoma. 6) Ewing's sarcoma usually occurs in the long bones of the lower limbs, generally in patients less than 15 years of age. The tumor metastasizes early, and about 4% of cases are found to have skull involvement. 8 ) Primary Ewing's sarcoma of the cranium is rare and constitutes only 1% of all Ewing's sarcomas. 1, 8, 27) The cell of origin has still not been established, but immunocytochemical techniques, electron microscopy, and cytogenetic studies suggest that neural tissue may be the common origin of Ewing's sarcoma, neuroblastoma, and the primitive neuroectodermal tumor of bone. 4, 16) We report a patient with primary Ewing's sarcoma of the cranium involving the occipitotemporal region who was treated with surgery, followed by radiotherapy and chemotherapy.
Case Report
A 17-year-old female was admitted to our hospital with 3 month history of swelling on her right occipitotemporal region and headache, vertigo, and vomiting. Clinical examination revealed right sensorineural deafness and neck stiffness. There were no other notable neurological findings. The occipital and posterior parts of the petrous bones were destroyed by the tumor extending to both the supratentorial and infratentorial spaces intracranially and the retroauricular subcutaneous tissue extracranially. Computed tomography (CT) showed the tumor was well enhanced with contrast medium (Fig.  1 ). Magnetic resonance (MR) imaging showed the tumor as isointense on both T 1 -and T 2 -weighted images. Moderate, uniform enhancement was seen after administration of intravenous contrast medium (Fig. 2) .
Histological examination of the tumor biopsy material revealed Ewing's sarcoma consisting of small round dark cells showing focal reaction to periodic acid-Schiff (PAS) and vimentin stains but no reaction to epithelial membrane antigen, keratin, neuron-specific enolase, leukocyte common antigen, and myoglobulin stains (Figs. 3 and 4). Based on these findings, the diagnosis was Ewing's sarcoma. Systemic examination and investigation revealed no evidence of metastatic spread.
The patient was treated surgically under the diagnosis of primary Ewing's sarcoma of the cranium. The tumor was removed via a right occipitotemporal craniectomy. The neoplasm had destroyed the involved right occipital bone and had invaded the dura Occipital Ewing's Sarcoma mater. The tumor was located at the junction of the transverse, sigmoid, and superior petrosal sinuses, which were totally blocked. The tumor had infiltrated down into the arachnoid membrane, and had invaded the brain tissue at one point. After excision of the tumor, the sinuses were ligated and duraplasty was performed with a fascia lata graft. The patient received postoperative radiotherapy and chemotherapy using vincristine (1.5 mg/m 2 intravenous weekly × 6 and every alternate × 6), cyclophosphamide (1200 mg/m 2 intravenous weekly × 6 and every alternate × 6), adriamycin (30 mg/m 2 intravenous daily × 2 every month × 6), and actinomycin-D (2 mg/m 2 intravenous once every month × 6). Fourteen months after surgery there was no evidence of local recurrence or distant metastases.
Discussion
Ewing's sarcoma is a malignant primary bone tumor that commonly affects children and young adults, 20) and represents 6-9% of all primary malignant bone tumors. Approximately 90% of cases occur in the F. S. Erol et al.
first and second decades, with the peak incidence between 5 and 13 years of age, but is very rare in adulthood. 27) Our patient was in the young adult group. Primary Ewing's sarcoma commonly affects the diaphysis of the long bones (47%), pelvis (29%), ribs and vertebrae (12%), and jaw and cranium (9%). 8, 28) Primary cranial Ewing's sarcoma accounts for approximately 1% of all Ewing's sarcoma cases. 1, 8, 27) The location is frequently the frontal and parietal convexities, 19, 27) and less often the squama and the mastoid process of the temporal bone, 5, 6, 11, 30) the ethmoid bone, 12) the orbit, 1, 26, 31) the petrous bone, 6, 8, 17, 22, 27) and the occipital bone. 6, 9, 32) Central nervous system involvement by secondary deposits from primary extracranial Ewing's sarcoma occurs in 10% to 33% of cases. 4, 6, 19) Early diagnosis is extremely important to obtain long-term survival because metastasis to the lungs and/or to other bones may occur in the very early stages of tumor development. 7, 23) Metastases to the cranium were found in 32% of cases and cerebral manifestations are common and occur within 2 years in 90% of cases. 15) In contrast to the frequent metastases from primary Ewing's sarcomas in general, metastases from primary Ewing's sarcoma of the cranium have not been reported. 6) Cranial CT or radiography of Ewing's sarcoma reveals lytic lesions with poor margination and often a`moth-eaten' appearance. The`onion-skin' appearance due to the periosteal reaction is more common in the long bones than in the spine. MR imaging shows the tumor as hypointense compared to normal bone on T 1 -weighted images and hypointense to hyperintense on T 2 -weighted images. Moderate, uniform enhancement is seen after administration of intravenous contrast medium. 30, 34) CT showed good enhancement with contrast medium, and MR imaging showed an isointense area on T 1 -and T 2 -weighted images in our patient.
Histologically, Ewing's sarcoma consists of round and dark cells. Neuroblastoma and lymphoma were excluded in the differential diagnosis of our case since neuron-specific enolase and leukocyte common antigen staining were negative. PAS staining with and without diastase treatment detects intracellular glycogen and favors the diagnosis of Ewing's sarcoma rather than metastatic neuroblastoma. 29) Various factors indicate a good outcome for patients with cranial Ewing's sarcoma: Duration of symptoms for a period of longer than 6 months; absence of fever or systemic symptoms; peripheral localization of the tumor and absence of metastases; initial lactate dehydrogenase levels of less than 170 IU/l; leukocyte count of less than 7000/dl; and lymphocyte count of less than 2000/dl. 1) The findings of our patient were consistent with these criteria.
Preoperatively, the tumor appears as a brownish vascular mass with invasion of muscle externally and dura internally. Brain invasion is rare, and may be mistaken for a glioma if present. 21) Radical surgery has been advocated, 1, 19, 30) but these tumors are sensitive to radio-and chemotherapy, so a less aggressive approach should be considered. 2) The most common symptoms of Ewing's sarcoma are pain and swelling. The characteristic signs are low-grade fever and general malaise. The size of the retroauricular mass had increased over 3 months in our patient.
The tumor is radiosensitive and a dose of 1.5-2.0 Gy/day for 5 days per week is recommended and must be followed by chemotherapy. A four-drug regimen (vincristine, adriamycin, cyclophosphamide, actinomycin-D) appears to be superior to a three-drug regimen (vincristine, adriamycin, cyclophosphamide). 13) Long-term survival can be expected in patients with Ewing's sarcoma when the tumor is radically excised, followed by radiation and chemotherapy. 24, 25) This appears to be true for cranial Ewing's sarcoma as well. Distinction of primary from metastatic cranial Ewing's sarcoma is definitely important as the primary tumor can often be successfully managed by intensive therapy, including radical excision.
